Incidence of Venous Thromboembolism and Professional Practices in Brest Area

Venous Thromboembolism Clinical Trial

— EPIGETBO III  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02895971
• Other study ID #: EPIGETBO III (RB 12.157)
• Status: Completed
• Phase: N/A
• First received: August 29, 2016
• Last updated: July 3, 2017
• Start date: March 4, 2013
• Est. completion date: June 30, 2017

Study information

• Verified date: July 2017
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study estimate VTE incidence. Investigators prospectively record all cases of symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT) of the lower limbs diagnosed between March 1, 2013 and February 28, 2014 in hospitals and in the community.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1416
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• symptomatic pulmonary embolism (PE) and deep vein thrombosis (DVT) diagnosis confirmed

• Patient living in Brest area from time of diagnosis

Exclusion Criteria:

• invalid diagnosis

• asymptomatic event

• Main residence patient out of Brest area.

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gathering information about potential factors predisposing Thromboembolic disease and treatments undertaken.	After two years, all medication given to the patient to treat his initial VTE will be recorded, as well as the ongoing of thromboembolic disease	two years after VTE